
ASK YOUR DOCTOR ABOUT THE TORUS2 CLINICAL TRIAL





WHAT IS PAD (PERIPHERAL ARTERY DISEASE)?

PAD happens when the arteries in your legs and feet are blocked by a buildup of fat and calcium. The blockage reduces blood flow and can lead to pain, loss of movement, and even amputation. This blockage is most commonly found in the superficial femoral artery (SFA) in your thigh. More than 200 million people worldwide are affected by PAD, a potentially life-threatening condition.¹



WHAT ARE SOME RISK FACTORS FOR PAD?²

Smoking, high blood pressure, diabetes, high cholesterol, and age over 60 years old are all risk factors of PAD. PAD can lead to a more serious condition, called CLI (Critical Limb Ischemia). CLI leads to severe pain in the feet or toes, even when resting. Patients with PAD are also at a greater risk for heart attack and stroke.

WHAT ARE COMMON SYMPTOMS OF PAD?³

Blockages reduce blood flow, which can lead to pain, muscle cramps, tightness, or weakness, especially during activity. Many patients do not experience symptoms in the early stages of PAD.

If PAD is left untreated, it can lead to:

- 1. Leg pain while walking
- 2. Leg numbness or weakness
- 3. Coldness on lower leg or foot
- **4.** Sores on toes, legs, or feet that won't heal.
- **5.** Change in color of legs

HOW IS PAD TREATED?⁴

PAD can be treated with medicine, surgery, and other procedures. Your doctor will work with you to create a treatment plan specifically for you.

WHAT IS THE TORUS2 CLINICAL STUDY?

Torus 2 is a Clinical Trial studying a new stent graft for the treatment of PAD in the SFA. The TORUS Stent Graft is a covered metal cage designed to open the blocked artery and allow blood to reach your legs and feet. The stent graft is placed through a small incision in the groin area.

WHY IS THIS STUDY BEING CONDUCTED?

To provide patients more options for the treatment of PAD. To help doctors create the best treatment plan for their patients.

WHO IS A GOOD CANDIDATE FOR THE TORUS2 CLINICAL STUDY?

Men and women, with symptoms of PAD in the lower limbs, who are able to return for follow up visits for 3 years after the procedure.

¹Kasapis, Christos, and Hitinder S. Gurm. "Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review." *Current cardiology reviews* 5, no. 4 (2009): 296-311.

Ask your doctor
if you are a
candidate for the
Torus2 Clinical Study

To learn more about the clinical study, visit www.pqbypass.com

²http://cardiovascularcoalition.com/wp-content/uploads/2015/05/PAD.pdf

³http://cardiovascularcoalition.com/wp-content/uploads/2015/05/PAD.pdf

⁴https://cardiovascularcoalition.com/cardiovascular-care/pad-intervention-2/

PQ Bypass, Inc. is a Silicon Valley-based medical device company developing the DETOUR Procedure for percutaneous femoropopliteal bypass and the TORUS Stent Graft.

The TORUS Stent Graft and DETOUR™ System are physician-driven innovations, created by Dr. James Joye and Dr. Richard Heuser, who are world-renowned experts and pioneers in the treatment of peripheral arterial disease.

The TORUS Stent Graft is limited by federal law to investigational use only and is not available for sale in the US.



1971 Milmont Drive Milpitas, CA 95035 www.pqbypass.com | 408.940.3520

©PQ Bypass 2020. All rights reserved.